Comment
Author: Admin | 2025-04-28
Not generally used as an antiemetic in critical illness, but could be considered as a palliative measure in patients with malignancy.Side effects include sedation, tachycardia, dry mouth, and visual hallucinations.More: ๐ MedScape monograph on dronabinolFollow us on iTunesquestions & discussion(back to contents)To keep this page small and fast, questions & discussion about this post can be found on another page here.If the patient doesn't respond to one antiemetic, switching to a different agent may not work (especially to a different agent with a similar mechanism of action). Rather, it may be more effective to add a second agent that acts at a different receptor.(25841474)Avoid rapid IV pushes of antiemetic agents, as this may increase the risk of side effects (especially QT prolongation with ondansetron, or extrapyramidal side effects with D2 receptor antagonists).Avoid D2 receptor antagonists in patients with Parkinson's disease.Be extremely cautious about the intravenous use of promethazine (or perhaps avoid this entirely). Extravasation or inadvertent intra-arterial administration of promethazine can cause tissue necrosis.Guide to emoji hyperlinks = Link to online calculator. = Link to Medscape monograph about a drug. = Link to IBCC section about a drug. = Link to IBCC section covering that topic. = Link to FOAMed site with related information. = Link to supplemental media.References16861255 Wallenborn J, Gelbrich G, Bulst D, et al. Prevention of postoperative nausea and vomiting by metoclopramide combined with dexamethasone: randomised double blind multicentre trial. BMJ. 2006;333(7563):324. doi:10.1136/bmj.38903.419549.80 [PubMed]17532704 Tarricone R, Girolami F. Economic Evaluation of a New Antiemetic Drug โ Palonosetron versus Ondansetron : Assessment of the Drug Price Ratio in Five European Countries. Clin Drug Investig. 2005;25(9):597-608. doi:10.2165/00044011-200525090-00005 [PubMed]24314899 Freedman SB, Uleryk E, Rumantir M, Finkelstein Y. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. Ann Emerg Med. 2014;64(1):19-25.e6. doi:10.1016/j.annemergmed.2013.10.026 [PubMed]25841470 Smith HS, Smith JM,
Add Comment